Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
When is chemotherapy too well tolerated? This Viewpoint discusses the possibilities that some patients receive inadequate doses of chemotherapy using the conventional dose calculation method based on body surface area and that a correlation between hematological toxicity and treatment efficacy could be used to titrate therapy.
The myoepithelial cell exerts profound effects on breast tumor cell behavior and resides close to abnormally proliferating breast epithelial cells in precancerous ductal carcinomain situ(DCIS) tumors. These cells also form a natural border separating breast epithelial cells from stromal angiogenesis. Barsky and Karlin discuss the role myoepithelial cells may have in inhibiting the progression of DCIS to invasive breast cancer, and the functional studies that are elucidating the anti-invasive and anti-angiogenic phenotypes of these cells.
Anemia can be a debilitating problem that negatively influences overall quality of life, and it can worsen the prognosis for cancer patients. The requirement for red-blood cell transfusions is reduced in patients receiving erythropoietin therapy. This review discusses quality of life issues, the thromboembolic complications associated with erythropoietin treatment, and provides a critical appraisal of the clinical trial data and evidence-based guidelines for erythropoietin treatment.
